The Full Federal Court has shot down Reckitt Benckiser’s appeal of a ruling that it misled consumers with claims that its Nurofen is a more effective pain killer than rival GlaxoSmithKline’s Panadol.
A Federal Court judge skipped vital witness testimony when he ruled Reckitt Benckiser misled consumers about the effectiveness of its Nurofen painkiller, the pharmaceutical company told the Full Federal Court Monday.
The final day of trial in the ACCC’s case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as ‘onerous’ a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant ‘inherited’ from Novartis.
The first day of a liability hearing in a consumer case over GlaxoSmithKline’s marketing for its popular Voltaren products has seen an ACCC witness deflect accusations the regulator was vague about its misleading packaging concerns, placing the blame squarely on the pharmaceutical giant.
GlaxoSmithKline is pushing for lower penalties in a case brought by the Australian Competition and Consumer Commission alleging the pharma giant breached the Australian Consumer Law in the marketing for its Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
IP Australia has ruled in part that cheese branded with the Asiago label need not be manufactured in the Asiago region in Italy, striking down an opposition to a trade mark filed by cheese producer Sartori Company.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.